

Contents

Contributors xv

Introduction xix

Robert L. Findling, M.D.

Acknowledgments xxiii

1

**Developmental Aspects of Pediatric
Psychopharmacology** 1

Benedetto Vitiello, M.D.

Pharmacokinetics 2

Pharmacodynamics 10

Efficacy 11

Safety 14

Ethical Aspects 18

Regulatory Aspects 21

Conclusions 24

Clinical Pearls 25

References 25

2

**Attention-Deficit/
Hyperactivity Disorder** 33

Natalya Paykina, M.A., and Laurence Greenhill, M.D.

Diagnosis of ADHD 34

Treatment of ADHD 39

Monitoring Treatment 76

Choice of Medication 78

Conclusions 79

Clinical Pearls 80

References 85

3 Disruptive Behavior Disorders and Aggression 99

Natoshia Raishevich, B.A., Elizabeth Pappadopulos, Ph.D., and Peter S. Jensen, M.D.

Epidemiology 101
Differential Diagnosis 102
Course and Outcome 104
Rationale and Justification for
 Psychopharmacological Treatment. 105
Issues in Study Design and Interpretation 106
Atypical Antipsychotics: Review of
 Treatment Studies 107
Typical Antipsychotics: Review of Treatment Studies . 114
Stimulants: Review of Treatment Studies. 119
Mood Stabilizers: Review of Treatment Studies 121
Other Agents 124
Safety Issues 126
Practical Management Strategies 128
Conclusions. 131
Clinical Pearls 132
References. 134

4 Anxiety Disorders. 143

Moira A. Rynn, M.D., and Jennifer Regan, B.A.

Epidemiology 144
Course and Outcome 145
Rationale and Justification for
 Psychopharmacological Treatment. 146
Medications for Pediatric Anxiety Disorders:
 Review of Treatment Studies. 147
Safety Issues 182
Practical Management Strategies 184
Conclusions. 187
Clinical Pearls 188
References. 188

5	Major Depressive Disorder	197
	<i>Boris Birmaher, M.D.</i>	
	Assessment of Treatment Response.	198
	Treatment Phases	198
	Treatment of Major Depressive Disorder With Selective Serotonin Reuptake Inhibitors and Other Novel Antidepressants.	199
	Treatment of Major Depressive Disorder Subtypes.	209
	Treatment of Comorbid Conditions and Suicidality	214
	Continuation Therapy.	215
	Maintenance Therapy.	216
	Clinical Pearls	219
	References.	220
6	Bipolar Disorders	229
	<i>Kevin W. Kuich, M.D., and Robert L. Findling, M.D.</i>	
	Lithium.	230
	Anticonvulsants.	235
	Maintenance Therapy.	244
	Atypical Antipsychotics.	244
	Combination Pharmacotherapy	256
	Conclusions.	257
	Clinical Pearls	258
	References.	259
7	Autism and Other Pervasive Developmental Disorders.	265
	<i>Kimberly A. Stigler, M.D., Craig A. Erickson, M.D., David J. Posey, M.D., and Christopher J. McDougle, M.D.</i>	
	Atypical Antipsychotics.	267
	Serotonin Reuptake Inhibitors.	274
	Mirtazapine	278
	Venlafaxine	278
	Buspirone	279
	Alpha ₂ -Adrenergic Agonists.	279

Psychostimulants	280
Atomoxetine	281
Beta-Adrenergic Antagonists	282
Mood Stabilizers	282
Cholinesterase Inhibitors	283
Glutamatergic Agents	284
Naltrexone	285
Secretin	285
Safety Issues	286
Practical Management Strategies	288
Conclusions	291
Clinical Pearls	291
References	292

8 Tic Disorders 301

Lawrence Scabill, M.S.N., Ph.D.

Epidemiology	302
Diagnosis and Assessment	303
Treatment of Tics in Children With Tourette's Syndrome	306
Treatment of OCD in Children With Tourette's Syndrome	313
Treatment of ADHD in Children With Tourette's Syndrome	319
Clinical Pearls	327
References	327

9 Schizophrenia and Psychotic Illnesses 337

*Judith L. Rapoport, M.D., Nitin Gogtay, M.D., and
Phillip Shaw, M.D., Ph.D.*

History and Classification of Psychosis in Children	338
Epidemiology	339
Course and Outcome	339
Rationale for Psychopharmacological Treatment . . .	340
Pharmacotherapy	341

Treatment of Comorbid Conditions	350
Side Effects	351
Early Intervention Studies	361
Clinical Pearls	365
References.....	366

**10 Disorders Primarily Seen in
General Medical Settings375**

John V. Campo, M.D.

Functional Somatic Syndromes and Somatoform Disorders.....	376
Eating Disorders	384
Sleep Disorders.....	386
Elimination Disorders.....	391
Agitation and Delirium.....	393
Borderline Personality Disorder.....	404
General Medical Conditions and Organ Failure.....	406
Clinical Pearls	413
References.....	413

Index425